权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Neurobiology and Treatment of Reading Disability in NF1

神经生物学和 NF1 阅读障碍的治疗

基本信息

批准号：
10628742
负责人：
Laurie E Cutting
金额：
$ 25.51万
依托单位：
VANDERBILT UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-01 至 2023-01-31
项目状态：
已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Neurofibromatosis Type 1 (NF1), an autosomal dominant neurocutaneous syndrome with an incidence of 1:3000, is caused by a mutation in neurofibromin -- a protein that negatively impacts learning by altering RAS signaling in long term potentiation (LTP). Clinically, NF1 shows four times greater rate of learning disabilities (65%) compared to the general population (15%), including reading disability (RD), resulting in educational impairment. The negative impact on academics makes these learning disabilities, including reading disability, among the most common concerns of parents of children with NF1. In previous research (NS49096), we demonstrated that children with NF-1 with reading difficulty (NF+RD) are able to respond to standard phonologically-based reading tutoring that was originally developed to treat children in the general population with idiopathic reading disability (IRD). Of central importance to this application, another line of research in the mouse model of NF has shown that pharmacological treatment (Lovastatin) reverses learning deficits (Li et al., 2005). The assumed mechanism is that Lovastatin, an HMGCoA reductase inhibitor, upregulates RAS signaling to counteract the negative LTP effects of deficient neurofibromin, thus allowing for better memory formation during learning. This finding has stimulated translational research to assess whether Lovastatin, a medication that the American Academy of Pediatrics to endorses as safe to use in children, can reverse cognitive deficits in humans with NF1. Promising results have been found in studies that, similar to the mouse studies, measure specific cognitive domains or pair Lovastatin with training of the deficient skill. Given that (a) NF+RD benefit from reading tutoring and (b) pharmaceutical benefits appear linked to specific study designs, several next steps are needed to better understand the behavioral and neural mechanisms of cognition in NF1. Specifically, we propose a clinical trial in which we pre-treat the NF+RD children with Lovastatin for the 12 weeks prior to reading tutoring, as compared to NF+RD who receive either reading tutoring or Lovastatin; critically, like animal studies, we will target those who show impaired learning on the specific skill to be taught, i.e., NF+RD will receive reading tutoring. Both behavioral and neurobiological measures are proposed, and changes in functional and structural connectivity are expected to occur with enhanced cognition. In particular, the combination of behavioral and pharmacological intervention is hypothesized to have a synergistic effect producing greater gains in cognition and changes in neurobiology than Lovastatin or tutoring alone. In sum, our overarching goal in this next phase of our research is to capitalize on current findings to elucidate mechanisms of and best treatments for the cognitive deficits in NF1. Such approach could also have a broader applicability for better understanding human learning mechanisms in developmental disorders.

项目总结/摘要 1型神经纤维瘤病（NF 1）是一种常染色体显性遗传的神经皮肤综合征， 1：3000，是由神经纤维蛋白的突变引起的-一种通过改变RAS对学习产生负面影响的蛋白质长时程增强（LTP）在临床上，NF 1表现出四倍的学习障碍率 (65与一般人群（15%）相比，包括阅读残疾（RD），损伤对学业的负面影响使得这些学习障碍，包括阅读障碍，这是NF 1患儿父母最关心的问题之一。在先前的研究（NS 49096）中，我们证明NF-1伴阅读困难（NF+RD）的儿童能够对标准的一种以语音为基础的阅读辅导，最初是为治疗普通人群中的儿童而开发的患有特发性阅读障碍（IRD）。对这一应用至关重要的是， NF的小鼠模型显示药物治疗（洛伐他汀）逆转学习缺陷（Li等， 2005年）。推测其机制是HMGCoA还原酶抑制剂洛伐他汀上调RAS 信号传导以抵消缺乏神经纤维蛋白的负LTP效应，从而允许更好的记忆在学习过程中形成。这一发现刺激了转化研究，以评估是否洛伐他汀，美国儿科学会认可的儿童安全用药， NF 1患者的认知缺陷。在研究中发现了有希望的结果，类似于小鼠研究，测量特定的认知领域或将洛伐他汀与缺乏技能的训练配对。鉴于（a） NF+RD受益于阅读辅导和（B）药物益处似乎与特定研究设计相关，接下来的几个步骤需要更好地理解NF 1中认知的行为和神经机制。具体来说，我们提出了一项临床试验，在该试验中，我们对12名NF+RD儿童进行了洛伐他汀预治疗，与接受阅读辅导或洛伐他汀的NF+RD组相比，阅读辅导前6周; 关键的是，像动物研究一样，我们将针对那些在要教授的特定技能上表现出学习障碍的人，也就是说，NF+RD将接受阅读辅导。提出了行为和神经生物学措施，随着认知能力的增强，预期功能和结构连接性会发生变化。特别是，行为和药物干预的组合被假设具有协同效应在认知和神经生物学方面的变化比单独使用洛伐他汀或辅导更大。总的来说，我们在下一阶段研究的首要目标是利用目前的发现来阐明 NF 1认知缺陷的机制和最佳治疗方法。这种方法也可以有一个更广泛的适用性，以更好地了解人类学习机制的发展障碍。